IN8BIO INC

INAB stock represents shares of IN8bio, Inc., a clinical-stage biotechnology company. The ticker trades on the Nasdaq exchange and gives investors exposure to the company's work in developing cell therapies, particularly gamma-delta T cell treatments for cancer. Because IN8bio is a clinical-stage firm, its stock is tied to the progress of its research programs rather than commercial product sales. For the latest price, market cap, and other live data on INAB, refer to the current quote displayed on this page.

INAB operates in the biotechnology industry, with a focus on cell therapy and immuno-oncology. The company is developing allogeneic gamma-delta T cell therapies intended to treat various cancers. As a clinical-stage biotech, its business centers on research, clinical trials, and regulatory milestones rather than the manufacturing and sale of approved drugs. This industry context is important because sector-wide developments, such as changes in FDA policy or competitor trial results, can affect how INAB stock trades.

INAB stock can be highly volatile, which is common for clinical-stage biotechnology companies. Its price often reacts sharply to news about clinical trial results, regulatory decisions, financing activities, and broader market sentiment toward small-cap biotech. Because the company does not yet have commercial revenue, investor expectations around its pipeline can drive significant swings. For current volatility measures such as beta or average trading volume, check the latest data on this page, as these figures change frequently.

The current price of INAB stock is not fixed and changes throughout the trading day. To see the latest quote, refer to the live price displayed at the top of this page. That figure reflects the most recent trade and may differ from the previous close, opening price, or after-hours levels. Because biotech stocks like INAB can move quickly, it is best to check the real-time data on this page before making any trading decisions.

Valuing INAB is not straightforward because clinical-stage biotechs often have no product revenue or earnings. Traditional metrics like the price-to-earnings ratio may not apply or may be negative. Instead, investors may look at cash position, research and development spending, pipeline progress, and potential market opportunities for its therapies. Comparing INAB to similar clinical-stage biotech peers can provide context, though each company's pipeline differs. For any current valuation metrics that are available, refer to the latest data on this page.

INAB carries risks typical of clinical-stage biotech companies. Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund research, potential delays or failures in regulatory approvals, and competition from larger or more advanced therapies. As a small-cap stock, INAB may also experience lower liquidity and higher price volatility. Broader market, economic, and interest rate changes can affect investor appetite for speculative biotech shares. Reviewing the company's SEC filings can help investors understand these risks in more detail.